title: Prednisone, oral etoposide, and novantrone for treatment of non-Hodgkin's lymphoma: a preliminary report.
authors.affiliation: Department of Hematology/Oncology, Toronto Hospital, Ontario, Canada.
authors.forename: P E
authors.initials: PE
authors.lastname: Goss
authors.forename: R
authors.initials: R
authors.lastname: Burkes
authors.forename: L
authors.initials: L
authors.lastname: Rudinskas
authors.forename: M
authors.initials: M
authors.lastname: King
authors.forename: W
authors.initials: W
authors.lastname: Chow
authors.forename: R
authors.initials: R
authors.lastname: Myers
authors.forename: M
authors.initials: M
authors.lastname: Davidson
authors.forename: P
authors.initials: P
authors.lastname: Poldre
authors.forename: M
authors.initials: M
authors.lastname: Crump
authors.forename: D
authors.initials: D
authors.lastname: Sutton
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011446:Prospective Studies
chemical_list: D005047:Etoposide; D008942:Mitoxantrone; D011241:Prednisone